胸苷酸合酶和胸苷酸磷化酶在进展期胃癌中的研究进展

摘要

5-fluorouracil (5-Fu) is a basic drug in the treatment of advanced gastric cancer. It is widely used in chemotherapy regimens for metastatic gastric cancer. However, the reaction rate was only 10%~30% when used 5-Fu alone. Interindividual variation in the enzyme activity of the 5-Fu metabolic pathway can affect the metabolism extent of 5-Fu and the efficacy of chemotherapy based on 5-Fu. In this review the roles of thymidylate synthase and thymi-dine phosphorylase enzymes factors involved in the 5-Fu metabolic pathway and the efficacy of fluoropyrimidine treat-ment in the metastatic gastric cancer are discussed.%5-氟尿嘧啶（5-Fu）是进展期胃癌化疗最基本的药物之一。基于5-Fu为主的化疗方案广泛应用于胃癌治疗。然而，单用5-Fu反应率仅为10%~30%。5-Fu代谢相关酶活性的个体差异影响着5-Fu在体内的代谢和5-Fu的治疗效果。本文就5-Fu代谢相关酶胸苷酸合酶（TS）、胸苷酸磷化酶（TP）在胃癌中的表达特点及对基于5-Fu为主的化疗方案效果的影响做一综述。